Global ethical code for human genome editing

Introduction

Human genome editing refers to the use of advanced technologies, particularly CRISPR-Cas9, to modify the genetic material of human cells. It offers significant possibilities for treating genetic disorders, preventing inherited diseases and improving medical research. However, it also raises serious ethical and legal concerns relating to human dignity, informed consent, genetic equality, privacy, public safety and the rights of future generations.

A global ethical code for human genome editing would establish common principles to guide governments, scientists, medical institutions and biotechnology companies. Although no single universally binding international code currently governs every aspect of human genome editing, several international declarations, guidelines and national laws provide important foundations for such a framework.

Meaning and objectives of a global ethical code

A global ethical code is a set of internationally recognised principles intended to ensure that human genome editing is conducted responsibly. Its primary objective is to encourage beneficial scientific research while preventing unsafe, discriminatory or unethical applications.

The code should distinguish between two major categories:

Somatic genome editing: Changes are made to body cells and generally affect only the treated individual. These changes are not ordinarily inherited by future generations.

Germline genome editing: Changes are made to reproductive cells or embryos and may be transmitted to future generations.

Somatic editing may have legitimate therapeutic applications under appropriate safety and regulatory conditions. Heritable genome editing raises substantially greater ethical concerns because future individuals cannot consent to genetic changes that may affect their descendants.

Core ethical principles

1. Human dignity and autonomy

Every individual must be treated with dignity and respect. Genome editing should not reduce human beings to collections of genetic characteristics or encourage the belief that certain genetic traits make people superior or inferior.

Individuals participating in genome-editing research must receive clear information about potential benefits, risks and uncertainties. Their participation should be voluntary and based on informed consent.

2. Safety and precautionary principle

Genome editing may produce unintended genetic changes, including off-target effects and unexpected biological consequences. Therefore, research must undergo scientific evaluation, independent ethical review and appropriate regulatory approval.

The precautionary principle requires additional caution where potential consequences may be serious or irreversible, particularly in heritable genome editing.

3. Justice and equality

Access to genome-editing technologies should not be restricted exclusively to wealthy individuals or countries. A global ethical framework should prevent genetic discrimination and ensure that technological development does not increase existing social inequalities.

4. Protection of future generations

Heritable genome editing affects individuals who cannot provide consent. Decisions must therefore consider long-term consequences, genetic diversity and the interests of future generations.

5. Transparency and accountability

Researchers and institutions should disclose research objectives, funding sources, conflicts of interest and significant findings. Unethical experimentation and deliberate concealment of adverse results should attract appropriate legal consequences.

International legal and ethical frameworks

Several international instruments provide foundations for global governance.

UNESCO Universal Declaration on the Human Genome and Human Rights, 1997: Recognises the human genome as part of the fundamental unity of humanity and emphasises human dignity, equality and protection against genetic discrimination.

UNESCO Universal Declaration on Bioethics and Human Rights, 2005: Establishes principles concerning informed consent, privacy, equality, social responsibility and protection of future generations.

International Covenant on Civil and Political Rights, 1966: Provides protections relating to privacy, equality and freedom from non-consensual medical or scientific experimentation.

WHO Recommendations on Human Genome Editing, 2021: Address governance, international cooperation, oversight mechanisms, registries and responsible research practices.

Oviedo Convention, 1997: For its parties, Article 13 restricts interventions seeking to modify the human genome, permitting them only for preventive, diagnostic or therapeutic purposes and not where the objective is to introduce modifications in descendants.

These instruments differ in legal status. Declarations and recommendations generally provide ethical guidance, whereas treaties create legal obligations for their parties.

Indian legal framework

India does not have one comprehensive statute specifically establishing a global-style ethical code for all human genome-editing activities. Instead, several laws and guidelines regulate relevant research and medical practices.

The Constitution provides important safeguards:

Article 14 protects equality before the law.

Article 21 protects life, personal liberty and human dignity.

Article 19 protects relevant freedoms, subject to constitutional restrictions.

The Drugs and Cosmetics Act, 1940, and New Drugs and Clinical Trials Rules, 2019, provide regulatory requirements relevant to clinical research and certain gene-therapy products. The National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019, issued by the Department of Biotechnology and ICMR, provide specialised guidance on research, safety and clinical development.

The ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017, also establish requirements concerning informed consent, ethical review and participant protection.

Important case laws

1. K.S. Puttaswamy v. Union of India (2017)

The Supreme Court recognised privacy as a fundamental right under Article 21 and other constitutional freedoms. The judgment is relevant to genome editing because genetic information is highly personal. Collection, storage and use of genetic data should therefore respect privacy, autonomy and lawful safeguards.

2. Suchita Srivastava v. Chandigarh Administration (2009)

The Supreme Court recognised reproductive autonomy as an important aspect of personal liberty under Article 21. This principle is relevant when considering decisions involving reproductive technologies and genetic interventions. However, the case did not directly decide the legality of human germline editing.

3. Samira Kohli v. Dr. Prabha Manchanda (2008)

The Supreme Court explained the importance of informed consent in medical treatment. Consent must be voluntary and based on adequate information. This principle is significant for genome-editing trials because participants must understand the nature, risks and possible consequences of genetic interventions.

4. Common Cause v. Union of India (2018)

The Supreme Court discussed dignity, autonomy and individual decision-making in the context of end-of-life care. Although unrelated directly to genome editing, its reasoning supports the broader ethical importance of respecting personal dignity and autonomy in medical decisions.

5. Vellore Citizens' Welfare Forum v. Union of India (1996)

The Supreme Court recognised the precautionary principle and polluter-pays principle as important components of Indian environmental law. The precautionary approach offers a useful analogy for regulating genome-editing technologies where scientific uncertainty may involve serious or irreversible consequences.

Challenges in establishing a global code

Creating a common international ethical code is difficult because countries have different cultural values, religious beliefs, legal systems and scientific capacities. Some countries may permit particular forms of genetic research, while others may prohibit them.

Other challenges include:

Lack of uniform international enforcement mechanisms.

Commercial pressure and competition between biotechnology companies.

Unequal access to advanced genetic treatments.

Risk of genetic discrimination and misuse of genetic information.

Difficulty in obtaining consent for research involving future generations.

Cross-border research and regulatory differences.

Recommendations for future governance

A comprehensive global ethical code should establish minimum international standards for human genome editing. It should require independent ethical approval, transparent research registration, strict informed-consent procedures and long-term safety monitoring.

It should also distinguish therapeutic applications from enhancement-based interventions. Any consideration of heritable genome editing should require exceptional scientific, ethical and public scrutiny, with appropriate legal safeguards.

International organisations such as WHO and UNESCO can encourage cooperation, while national governments should establish effective regulatory authorities and penalties for serious violations.

Conclusion

A global ethical code for human genome editing is essential to ensure that scientific progress remains consistent with human dignity, equality, safety and individual autonomy. Existing international declarations, WHO recommendations and national legal frameworks provide an important foundation, but differences in national regulation create governance gaps. A coordinated international framework should promote responsible therapeutic research, prevent discrimination and protect future generations from unacceptable genetic risks.